Most Read This Week
- Pyrotinib Plus Metronomic Etoposide for Heavily Pretreated HER2-Positive Metastatic Breast Cancer
- Next-Generation Oral SERD Camizestrant vs Fulvestrant in Postmenopausal ER+/HER2− Advanced Breast Cancer
- Efficacy and Safety of Trastuzumab Duocarmazine in Pretreated Patients With HER2+ Advanced or Metastatic Breast Cancer
- Clinicopathological Characteristics, Treatment Patterns, and Outcomes in Patients With HER2+ Breast Cancer Based on HR Status
- Intracranial Outcomes Following Neurosurgical Resection in Patients With Brain Metastases Secondary to HER2+ Breast Cancer vs Other Subtypes
Recently Updated
- Intracranial Outcomes Following Neurosurgical Resection in Patients With Brain Metastases Secondary to HER2+ Breast Cancer vs Other Subtypes
- Real-World Evidence on Prescribing Patterns and Clinical Outcomes in Patients With MBC Treated With PARP Inhibitors
- Pyrotinib Plus Metronomic Etoposide for Heavily Pretreated HER2-Positive Metastatic Breast Cancer
- 2024 Top Story in Oncology: Shifting the Scales — CDK4/6 Inhibitors and the Journey to Lower Recurrence Risk in Early-Stage Breast Cancer
- 2024 Top Story in Oncology: Lancet Breast Cancer Commission — An Equity-Based Perspective on Global Cancer Management